These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 2771989)

  • 1. BCG in superficial bladder cancer. EORTC Genitourinary Group Monograph 6. Proceedings of a meeting. Kerkrade, The Netherlands, September 7-8, 1988.
    Prog Clin Biol Res; 1989; 310():1-381. PubMed ID: 2771989
    [No Abstract]   [Full Text] [Related]  

  • 2. BCG therapy for superficial bladder cancer: fundamental aspects.
    Hudson ML; Ratliff TL
    In Vivo; 1991; 5(6):643-6. PubMed ID: 1810450
    [No Abstract]   [Full Text] [Related]  

  • 3. BCG in the management of superficial bladder cancer.
    Robinson MR
    Prog Clin Biol Res; 1985; 185B():161-6. PubMed ID: 3898140
    [No Abstract]   [Full Text] [Related]  

  • 4. Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy. Introduction.
    Lamm DL
    Eur Urol; 1995; 27 Suppl 1():1. PubMed ID: 7750524
    [No Abstract]   [Full Text] [Related]  

  • 5. Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview.
    van der Meijden AP; Debruyne FM; Steerenberg PA; de Jong WH
    Prog Clin Biol Res; 1989; 310():11-33. PubMed ID: 2672011
    [No Abstract]   [Full Text] [Related]  

  • 6. Intravesical instillation of BCG in carcinoma in situ of the urinary bladder. EORTC protocol 30861. EORTC-GU Group.
    Jakse G
    Prog Clin Biol Res; 1989; 310():187-92. PubMed ID: 2771992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Our experience in the treatment of superficial cancer of the bladder with BCG].
    Martínez E; Díaz I; Salvador J; Viladoms JM; Zungri E; Solé-Balcells FJ
    Arch Esp Urol; 1989 May; 42(4):325-7. PubMed ID: 2782959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897).
    Van der Meijden AP; Hall RR; Macaluso MP; Pawinsky A; Sylvester R; Van Glabbeke M
    Eur Urol; 1996; 29(2):199-203. PubMed ID: 8647147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCG immunotherapy in superficial cancer of the bladder.
    Levinson IP; van Blerk PJ
    S Afr J Surg; 1985 Jun; 23(2):53-4. PubMed ID: 3895464
    [No Abstract]   [Full Text] [Related]  

  • 10. EORTC Genitourinary Group Monograph 3: Developments in bladder cancer. Proceedings of the First International Consensus Development Conference on Guidelines for Clinical Research in Bladder Cancer. Antwerp, Belgium, June 20-22, 1985.
    Prog Clin Biol Res; 1986; 221():1-328. PubMed ID: 3543940
    [No Abstract]   [Full Text] [Related]  

  • 11. BCG-RIVM: a new BCG preparation for intravesical immunotherapy of superficial bladder cancer.
    Schreinemachers L; Van der Meyden A; Steerenberg P; Feitz W; Groothuis D; De Jong W; Debruyne F
    Chemioterapia; 1987 Jun; 6(2 Suppl):713-6. PubMed ID: 3334665
    [No Abstract]   [Full Text] [Related]  

  • 12. Complications of bacillus Calmette-Guerin (BCG) immunotherapy in superficial bladder cancer.
    Sosnowski JT
    Compr Ther; 1994; 20(12):695-701. PubMed ID: 7882653
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunotherapy in superficial bladder carcinoma].
    Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
    Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BCG in the treatment of superficial transitional cell carcinoma of the urinary bladder].
    Leibovici D; Zisman A; Lindner A
    Harefuah; 1999 Apr; 136(8):628-33. PubMed ID: 10955074
    [No Abstract]   [Full Text] [Related]  

  • 15. Use of Bacillus Calmette-Guerin in superficial bladder cancer: a review.
    Talug C; Brown ET; Zaslau S; Kandzari SJ
    W V Med J; 2009; 105(3):17-9. PubMed ID: 19456033
    [No Abstract]   [Full Text] [Related]  

  • 16. Advances in the treatment of superficial bladder cancer: optimizing BCG immunotherapy. Proceedings of a symposium. International Society of Urology, Sydney, Australia, September 18, 1994.
    Eur Urol; 1995; 27 Suppl 1():1-33. PubMed ID: 7750525
    [No Abstract]   [Full Text] [Related]  

  • 17. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
    Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
    Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCG in bladder cancer.
    Meek D
    Nurs Times; 1994 Oct 26-Nov 1; 90(43):34-5. PubMed ID: 7984457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preventive treatment of superficial tumors of the bladder using intravesical BCG. Review].
    Patard JJ; Chopin DK
    Ann Urol (Paris); 1993; 27(1):24-30. PubMed ID: 8470876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.